{
  "compound": "Various cannabinoid formulations",
  "condition": "MULTIPLE_SCLEROSIS",
  "effect_size": "Medium protective effect (HR = 0.69)",
  "study_type": "OBSERVATIONAL",
  "source": "NORML:MS_OBSERVATIONAL_002",
  "participants": "498 MS patients (longitudinal cohort)",
  "year": 2015,
  "notes": "Cannabinoids and Disease Progression in Multiple Sclerosis",
  "confidence": "medium",
  "abstract": "Cannabinoid users: 31% slower EDSS progression over 4 years vs non-users (HR = 0.69, p=0.02); neuroprotective signal"
}